ImmunoCellular Therapeutics, Ltd. (IMUC)
$
0.16
Key metrics
Financial statements
Free cash flow per share
-0.0126
Market cap
14.7 Million
Price to sales ratio
0
Debt to equity
-0.8318
Current ratio
0.0724
Income quality
0.8817
Average inventory
0
ROE
0.3264
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
News
defenseworld.net
a month ago
Shares of EOM Pharmaceutical Holdings, Inc. (OTCMKTS:IMUC - Get Free Report) rose 139% during trading on Monday. The company traded as high as $0.2180 and last traded at $0.2180. Approximately 12,218 shares were traded during mid-day trading, an increase of 535% from the average daily volume of 1,924 shares. The stock had previously closed
prnewswire.com
2 years ago
MONTVALE, N.J. , Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613.
prnewswire.com
2 years ago
Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J. , Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc (OTC: IMUC) ("EOM") today announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613.
prnewswire.com
5 years ago
LOS ANGELES, June 28, 2021 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will be applicable in September 2021.
See all news
